Orion’s financial objectives are ensuring the Group’s financial stability and creating a foundation for long-term profitable growth.

The principal means of achieving these objectives are:

• improving the organic development of net sales and operating profit through product, product portfolio and corporate acquisitions
• increasing the efficiency of operations and cost control
• maintaining a stable financial position, with the equity ratio at least 50%

Sales of Stalevo and Comtess/Comtan currently account for approximately one-third of Orion’s net sales. The key patents for these Parkinson’s drugs in Orion’s main markets will expire in 2012–2013, which is why their sales are expected to decline over the next few years. Orion is continuously bringing new products to the market to replace this drop in net sales.

The development of Orion’s net sales and profitability in the next few years will depend on how fast the sales of Parkinson’s drugs will decline and, on the other hand, how the sales of other products will increase in the future. This creates a point of discontinuity in the Group’s operations.